Federal Register / Vol. 85, No. 249 / Tuesday, December 29, 2020 / Notices 85831 

28 17 CFR 200.30–3(a)(12). 

cautioned that we do not redact or edit 

personal identifying information from 

comment submissions. You should 

submit only information that you wish 

to make available publicly. All 

submissions should refer to File 

Number SR–NYSEARCA–2020–112 and 

should be submitted on or before 

January 19, 2021. 

For the Commission, by the Division of 

Trading and Markets, pursuant to delegated 

authority.28

J. Matthew DeLesDernier, 

Assistant Secretary. 

[FR Doc. 2020–28659 Filed 12–28–20; 8:45 am] 

BILLING CODE 8011–01–P 

SECURITIES AND EXCHANGE 

COMMISSION 

Proposed Collection; Comment 

Request 

Upon Written Request, Copies Available 

From: Securities and Exchange 

Commission, Office of FOIA Services, 

100 F Street NE, Washington, DC 

20549–2736 

Extension: 

Form 2–E, Report pursuant to rule 609 of 

Regulation E, SEC File No. 270–222, 

OMB Control No. 3235–0233 

Notice is hereby given that, pursuant 

to the Paperwork Reduction Act of 1995 

(44 U.S.C. 3501 et seq.), the Securities 

and Exchange Commission (the 

‘‘Commission’’) is soliciting comments 

on the collection of information 

summarized below. The Commission 

plans to submit this existing collection 

of information to the Office of 

Management and Budget (‘‘OMB’’) for 

extension and approval. 

Rule 609 (17 CFR 230.609) under the 

Securities Act of 1933 (15 U.S.C. 77a et 

seq.) requires small business investment 

companies and business development 

companies that have engaged in 

offerings of securities that are exempt 

from registration pursuant to Regulation 

E under the Securities Act of 1933 (17 

CFR 230.601 to 610a) to report semiannually on Form 2–E (17 CFR 239.201) 

the progress of the offering. The form 

solicits information such as the dates an 

offering commenced and was completed 

(if completed), the number of shares 

sold and still being offered, amounts 

received in the offering, and expenses 

and underwriting discounts incurred in 

the offering. The information provided 

on Form 2–E assists the staff in 

monitoring the progress of the offering 

and in determining whether the offering 

has stayed within the limits set for an 

offering exempt under Regulation E. 

The Commission estimates that, on 

average, approximately one respondent 

submits a Form 2–E filing each year. 

The Commission further estimates that 

this information collection imposes an 

annual burden of four hours and 

imposes an annual external cost burden 

of zero. 

The collection of information under 

Form 2–E is mandatory. The 

information provided by the form will 

not be kept confidential. An agency may 

not conduct or sponsor, and a person is 

not required to respond to, a collection 

of information unless it displays a 

currently valid OMB control number. 

Written comments are invited on: (a) 

Whether the proposed collection of 

information is necessary for the proper 

performance of the functions of the 

agency, including whether the 

information will have practical utility; 

(b) the accuracy of the agency’s estimate 

of the burden of the collection of 

information; (c) ways to enhance the 

quality, utility, and clarity of the 

information collected; and (d) ways to 

minimize the burden of the collection of 

information on respondents, including 

through the use of automated collection 

techniques or other forms of information 

technology. Consideration will be given 

to comments and suggestions submitted 

in writing within 60 days of this 

publication. 

Please direct your written comments 

to David Bottom, Director/Chief 

Information Officer, Securities and 

Exchange Commission, c/o Cynthia 

Roscoe, 100 F Street NE, Washington, 

DC 20549; or send an email to: PRA_

Mailbox@sec.gov. 

Dated: December 22, 2020. 

Eduardo A. Aleman, 

Deputy Secretary. 

[FR Doc. 2020–28769 Filed 12–28–20; 8:45 am] 

BILLING CODE 8011–01–P 

OFFICE OF THE UNITED STATES 

TRADE REPRESENTATIVE 

Notice of Product Exclusion 

Extensions and Additional 

Modifications: China’s Acts, Policies, 

and Practices Related to Technology 

Transfer, Intellectual Property, and 

Innovation 

AGENCY: Office of the United States 

Trade Representative (USTR). 

ACTION: Notice of product exclusion 

extensions and additional 

modifications. 

SUMMARY: In prior notices, the U.S. 

Trade Representative modified the 

action in the Section 301 investigation 

of China’s acts, policies, and practices 

related to technology transfer, 

intellectual property, and innovation by 

excluding from additional duties certain 

medical-care products needed to 

address the COVID–19 outbreak. On 

March 25, 2020, the U.S. Trade 

Representative sought public comment 

on additional modifications in this 

investigation in order to address 

COVID–19. This notice announces the 

U.S. Trade Representative’s 

determination to extend certain product 

exclusions and to make further 

modifications to remove Section 301 

duties from additional medical-care 

products to address COVID–19. 

DATES: The product exclusion 

extensions announced in this notice 

will extend the exclusions through 

March 31, 2021. The modifications to 

exclude additional products will apply 

as of January 1, 2021 until March 31, 

2021. U.S. Customs and Border 

Protection will issue instructions on 

entry guidance and implementation. 

FOR FURTHER INFORMATION CONTACT: For 

general questions about this notice, 

contact Associate General Counsel 

Philip Butler, Assistant General 

Counsels Benjamin Allen or Susie Park 

Hodge, or Director of Industrial Goods 

Justin Hoffmann at (202) 395–5725. For 

specific questions on customs 

classification or implementation of the 

product exclusions identified in the 

Annexes to this notice, contact 

traderemedy@cbp.dhs.gov. 

SUPPLEMENTARY INFORMATION: 

A. Background 

At the direction of the President, the 

U.S. Trade Representative imposed 

additional duties on products of China 

in order to obtain the elimination of the 

unfair and damaging acts, policies, and 

practices identified in this investigation. 

These additional duties were imposed 

in four tranches. See 83 FR 28719 (June 

20, 2018), 83 FR 40823 (August 16, 

2018), 83 FR 47974 (September 21, 

2018), as modified by 83 FR 49153 

(September 28, 2018), and 84 FR 43304 

(August 20, 2019), as modified by 84 FR 

69447 and 85 FR 3741. 

For each tranche, the U.S. Trade 

Representative established a process by 

which U.S. stakeholders could request 

the exclusion of particular products 

subject to the action. Additionally, the 

U.S. Trade Representative later 

established a process by which U.S. 

stakeholders could request the 

extension of particular exclusions. 

Throughout the exclusion process, 

USTR assessed medical necessity in 

granting exclusions, consistent with its 

published criteria. In addition, the U.S. 


KHAMMOND on DSKJM1Z7X2PROD with NOTICES